Cargando…

In vitro activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer

BACKGROUND: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics. OBJECTIVES: We evaluated the in vitro activity of eravacycline (a recently developed fluorocycline) and comparators against bacterial pathogens isolated fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rolston, Kenneth, Gerges, Bahgat, Nesher, Lior, Shelburne, Samuel A, Prince, Randall, Raad, Issam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981869/ https://www.ncbi.nlm.nih.gov/pubmed/36875177 http://dx.doi.org/10.1093/jacamr/dlad020

Ejemplares similares

The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer
por: Gerges, Bahgat, et al.
Publicado: (2023)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
por: Rolston, Kenneth V. I., et al.
Publicado: (2020)

2122. In Vitro Activity of Cefepime-Taniborbactam Against Clinically Significant Gram-Negative Bacteria Isolated from Patients with Cancer
por: Gerges, Bahgat Z, et al.
Publicado: (2023)

2124. Novel Polygalacturonic and Caprylic Acid (PG+CAP) Antimicrobial Wound Ointment Effectiveness in Eradicating C. auris Biofilms In Vitro
por: Truong, Y Lan, et al.
Publicado: (2023)

2283. The Impact of a Booster Dose at the Age of 18 on Immunization Against Hepatitis B 4 Years Later
por: Vertkin, Liza, et al.
Publicado: (2018)

Post-Obstructive Pneumonia in Patients with Cancer: A Review
por: Rolston, Kenneth V. I., et al.
Publicado: (2018)

Febrile Neutropenia in Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2018)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Current Microbiology of Surgical Site Infections in Patients with Cancer: A Retrospective Review
por: Rolston, Kenneth V. I., et al.
Publicado: (2014)

Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options
por: Bartal, Carmi, et al.
Publicado: (2022)

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

2123. Novel Antimicrobial Polycarbonate Coating for Intravenous Connectors
por: Truong, Y Lan, et al.
Publicado: (2023)

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study
por: Zou, Xuehan, et al.
Publicado: (2023)

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
por: Zeng, Weiliang, et al.
Publicado: (2022)

810. Resistance to the Minocycline-Rifampin-Chlorhexidine (MRCH) combination does not emerge in biofilms of Tetracycline and Rifampin resistant bacteria grown on MRCH catheters depleted below antimicrobially effective concentrations
por: Gerges, Bahgat, et al.
Publicado: (2020)

Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance
por: Zhang, Fan, et al.
Publicado: (2018)

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
por: Brauncajs, Małgorzata, et al.
Publicado: (2023)

683. Assessment of Biofilm Eradication and Cytotoxicity of a Novel Polygalacturonic Acid + Caprylic Acid Wound Ointment Compared with Antiseptic Wound Ointments
por: Gerges, Bahgat, et al.
Publicado: (2019)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
por: Sun, Xiang, et al.
Publicado: (2021)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China
por: Zhao, Chunjiang, et al.
Publicado: (2019)

In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex
por: Chew, Ka Lip, et al.
Publicado: (2021)

In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria
por: Zhang, Tingting, et al.
Publicado: (2022)

Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro
por: Li, Anqi, et al.
Publicado: (2023)

Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
por: Wen, Zewen, et al.
Publicado: (2020)

Enhanced Biofilm Eradication and Reduced Cytotoxicity of a Novel Polygalacturonic and Caprylic Acid Wound Ointment Compared with Common Antiseptic Ointments
por: Gerges, Bahgat Z., et al.
Publicado: (2021)

The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review
por: Reitzel, Ruth A, et al.
Publicado: (2020)

Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates
por: Deolankar, Manas S., et al.
Publicado: (2022)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019
por: Chen, Jiawei, et al.
Publicado: (2023)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

1163. Minocycline EDTA Ethanol (MEDTA+EtOH) Lock Is Highly Efficacious in Rapidly Eradicating Candida auris Biofilm
por: Reitzel, Ruth A, et al.
Publicado: (2019)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals
por: Iregui, Alejandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d28tvhl6apqo92qurmu1h1oeug